• Cap de grup, Grup d’Oncology Data Science (ODysSey)
• Investigador científic, Grup d’Oncologia Computacional, Sage Bionetworks

• Integració de la recerca clínica i translacional amb la genòmica per a la teràpia de precisió del càncer
• Informes estandarditzats de les proves de seqüenciació de nova generació i debats dins dels comitès de tumors moleculars
• Recerca col·laborativa en genòmica del càncer, oncologia computacional i dades reals
• Solucions informàtiques i digitals per als sistemes de suport a les decisions clíniques i de laboratori en l’oncologia de precisió

Sánchez-Guixé M, Hierro C, Jiménez J, Viaplana C, Villacampa G, Monelli E, Brasó-Maristany F, Ogbah Z, Parés M, Guzmán M, Grueso J, Rodríguez O, Oliveira M, Azaro A, Garralda E, Tabernero J, Casanovas O, Scaltriti M, Prat A, Dienstmann R, Nuciforo P, Saura C, Graupera M, Vivancos A, Rodon J, Serra V. High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. Clin Cancer Res. 2022 Jan 1;28(1):137-149.

Pedrola A, Franch-Expósito S, Lahoz S, Esteban-Fabró R, Dienstmann R, Bassaganyas L, Camps J. PCIG: a web-based application to explore immune-genomics interactions across cancer types. Bioinformatics. 2022 Apr 12;38(8):2374-2376.

Villacampa G, Tolosa P, Salvador F, Sánchez-Bayona R, Villanueva L, Dienstmann R, Ciruelos E, Pascual T. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2022 Mar;104:102352.

Verdaguer H, Saurí T, Acosta DA, Guardiola M, Sierra A, Hernando J, Nuciforo P, Miquel JM, Molero C, Peiró S, Serra-Camprubí Q, Villacampa G, Aguilar S, Vivancos A, Tabernero J, Dienstmann R, Macarulla T. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma. Clin Cancer Res. 2022 Apr 14;28(8):1662-1671.

Villacampa G, Tolosa P, Salvador F, Sánchez-Bayona R, Villanueva L, Dienstmann R, Ciruelos E, Pascual T. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2022 Mar;104:102352.

Pellegrino B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, Moles-Fernández A, Viaplana C, Villacampa G, Guzmán M, Rodríguez O, Grueso J, Jiménez J, Arenas EJ, Degasperi A, Dias JML, Forment JV, O’Connor MJ, Déas O, Cairo S, Zhou Y, Musolino A, Caldas C, Nik-Zainal S, Clarke RB, Nuciforo P, Díez O, Serres-Créixams X, Peg V, Espinosa-Bravo M, Macarulla T, Oaknin A, Mateo J, Arribas J, Dienstmann R, Bellet M, Oliveira M, Saura C, Gutiérrez-Enríquez S, Balmaña J, Serra V. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Res. 2022 Apr 15;82(8):1646-1657.

Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Braña I, De Petris L, Yachnin J, Baird RD, Loriot Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, Vernieri C, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium; Balmaña J, Apolone G, Caldas C, Bergh J, Ernberg I, Fröhling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtiö J. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer. 2022 Feb;3(2):251-261.

Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, Michiels S, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER⁺ breast cancer. Nat Commun. 2022 Sep 7;13(1):5258.

Jácome AA, Peixoto RD, Gil MV, Ominelli J, Prolla G, Dienstmann R, Eng C. Biologics in rectal cancer. Expert Opin Biol Ther. 2022 Oct;22(10):1245-1257.

Biologics in rectal cancer.

Dienstmann R, Lonardi S. Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice? Lancet Oncol. 2022 Sep;23(9):1129-1131.

Le Tourneau C, Perret C, Hackshaw A, Blay JY, Nabholz C, Geissler J, Do T, von Meyenn M, Dienstmann R. An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry. JCO Precis Oncol. 2022 Jul;6:e2200019.

Villacampa G, Hernando-Calvo A, Berché R, Saavedra O, Marmolejo D, Mirallas O, Braña I, Muñoz-Couselo E, Garralda E, Dienstmann R. Response to “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias”. Cancer Treat Rev. 2022 Dec;111:102465.

Elez E, Ros J, Fernández J, Villacampa G, Moreno-Cárdenas AB, Arenillas C, Bernatowicz K, Comas R, Li S, Kodack DP, Fasani R, Garcia A, Gonzalo-Ruiz J, Piris-Gimenez A, Nuciforo P, Kerr G, Intini R, Montagna A, Germani MM, Randon G, Vivancos A, Smits R, Graus D, Perez-Lopez R, Cremolini C, Lonardi S, Pietrantonio F, Dienstmann R, Tabernero J, Toledo RA. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF^V600E metastatic colorectal cancer. Nat Med. 2022 Oct;28(10):2162-2170.

Brown S, Lavery JA, Shen R, Martin AS, Kehl KL, Sweeney SM, Lepisto EM, Rizvi H, McCarthy CG, Schultz N, Warner JL, Park BH, Bedard PL, Riely GJ, Schrag D, Panageas KS; AACR Project GENIE Consortium. Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies. JAMA Oncol. 2022 Feb 1;8(2):287-291.

Van Egeren D, Kohli K, Warner JL, Bedard PL, Riely G, Lepisto E, Schrag D, LeNoue-Newton M, Catalano P, Kehl KL, Michor F; AACR Project GENIE Consortium represented by Shawn Sweeney. Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. Sci Rep. 2022 Nov 9;12(1):19055.

Duarte FA, Ferreira CG, Dienstmann R, Ferrari BL, Costa E Silva M, Nazareth A Junior P, Guilherme de O Salles P, Henrique C Diniz P. Barriers in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World Evidence Scenario. J Mark Access Health Policy. 2022 May 24;10(1):2077905.

Élez E, Mulet-Margalef N, Sanso M, Ruiz-Pace F, Mancuso FM, Comas R, Ros J, Argilés G, Martini G, Sanz-Garcia E, Baraibar I, Salvà F, Noguerido A, Cuadra-Urteaga JL, Fasani R, Garcia A, Jimenez J, Aguilar S, Landolfi S, Hernández-Losa J, Braña I, Nuciforo P, Dienstmann R, Tabernero J, Salazar R, Vivancos A. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy. Int J Mol Sci. 2022 Dec 21;24(1):118. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.

Resende CAA, Fernandes Cruz HM, Costa E Silva M, Paes RD, Dienstmann R, Barrios CHE, Goncalves AC, Cascelli FGA, Souto AKBA, Oliveira LC, Reinert T, Andrade DAP, Passos MP, Millen EC, Zerwes F, Moraes PL, Ferrari BL, Mano MS. Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in Brazil. JCO Glob Oncol. 2022 Nov;8:e2200289.

Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, Lopez-Corral L, van Aalderen M, Kwon M, Martínez-Cibrian N, Bramanti S, Reguera-Ortega JL, Camacho-Arteaga L, Schmidt C, Marín-Niebla A, Kersten MJ, Martin Garcia-Sancho A, Zinzani PL, Corradini P, van Meerten T, Subklewe M, Barba P. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022 Jun 28;6(12):3606-3610.

Papakonstantinou A, Gonzalez NS, Pimentel I, Suñol A, Zamora E, Ortiz C, Espinosa-Bravo M, Peg V, Vivancos A, Saura C, Villacampa G, Oliveira M. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis. Cancer Treat Rev. 2022 Mar;104:102362.

Remon J, Hendriks LEL, Mountzios G, García-Campelo R, Saw SPL, Uprety D, Recondo G, Villacampa G, Reck M. MET alterations in NSCLC-Current Perspectives and Future Challenges. J Thorac Oncol. 2022 Oct 29:S1556-0864(22)01865-2.

Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, González B, Arance A, Martín-Liberal J, Gavilá J, López-González A, Cejalvo JM, Izarzugaza Y, Amillano K, Corbacho JG, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesía R, Cervantes A, Tabernero J. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Future Oncol. 2022 Oct 6.

Jiménez M, Roldán E, Fernández-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, Peralta-Garzón S, Pujadas G, Hernández C, Pagès C, Gironella M, Fox L, Orti G, Barba P, Pumarola T, Cabirta A, Catalá E, Valentín M, Marín-Niebla A, Orfao A, González M, Campins M, Ruiz-Camps I, Valcárcel D, Bosch F, Hernández M, Crespo M, Esperalba J, Abrisqueta P. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022 Feb 8;6(3):774-784.

Zurita AJ, Graf RP, Villacampa G, Raskina K, Sokol E, Jin D, Antonarakis ES, Li G, Huang RSP, Casanova-Salas I, Vivancos A, Carles J, Ross JS, Schrock AB, Oxnard GR, Mateo J. Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. JCO Precis Oncol. 2022 Jul;6:e2200195.

Abrisqueta P, Medina D, Villacampa G, Lu J, Alcoceba M, Carabia J, Boix J, Tazón-Vega B, Iacoboni G, Bobillo S, Marín-Niebla A, González M, Zenz T, Crespo M, Bosch F. A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression. Blood Adv. 2022 Nov 8;6(21):5763-5773.

Villacampa G, Falato C, Paré L, Hernando C, Arumí M, Saura C, Gómez G, Muñoz M, Gil-Gil M, Izarzugaza Y, Ferrer N, Najera-Zuloaga J, Montaño A, Ciruelos E, González-Santiago S, Villagrasa P, Gavilá J, Prat A, Pascual T. Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial. Eur J Cancer. 2022 Oct;174:232-242.

Vila CM, Moreno FA, Estébanez MM, Ares GR, Villacampa G, Dashti P, Oberoi HS, Martin-Huertas R, Jares P, Alos L, Teixido C, Rull R, Sanchez M, Malvehy J, Carcelero E, Valduvieco I, Fernandez AA. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution. Clin Transl Oncol. 2022 Feb;24(2):319-330.

Carrasco E, López-Fernández A, Codina-Sola M, Valenzuela I, Cueto-González AM, Villacampa G, Navarro V, Torres-Esquius S, Palau D, Cruellas M, Torres M, Perez-Dueñas B, Abulí A, Diez O, Sábado-Álvarez C, García-Arumí E, Tizzano EF, Moreno L, Balmaña J. Clinical and psychological implications of secondary and incidental findings in cancer susceptibility genes after exome sequencing in patients with rare disorders. J Med Genet. 2022 Nov 29:jmg-2022-108929.

Garcia-Duran C, Grau F, Villacampa G, Oaknin A. ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation. Int J Gynecol Cancer. 2022 Apr 20:ijgc-2022-003370.

Evidence-based neoadjuvant endocrine therapy for breast cancer Dienstmann R, Bines J. Clin Breast Cancer 2006;7(4):315-20.
Phase II trial of neoadjuvant chemotherapy using alternating doublets in non-small cell lung cancer Martins RG, Dienstmann R, Biasi P, Dantas K, Santos VO, Toscano E, Roriz W, Zamboni M, Sousa A, Ferreira CG, Small I, Moreira D, Zukin M. Clin Lung Cancer 2007;8(4):257-63.
Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with invasive bladder carcinoma Herchenhorn D, Dienstmann R, Peixoto FA, Campos FS, Santos VO, Moreira DM, Cardoso H, Small I, Ferreira CG. Int Braz J Urol 2007;33(5):630-8.
Palliative percutaneous nephrostomy in recurrent cervical cancer: Retrospective analysis of 50 consecutive cases Dienstmann R, Pinto CS, Pereira MT, Small I, Ferreira CG. J Pain Symptom Manage 2008;36(2):185-90.
XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy Pinho MB, Costas F, Sellos J, Dienstmann R, Andrade PB, Herchenhorn D, Peixoto FA, Santos VO, Small IA, Guimarães DP, Ferreira CG. Urol Oncol 2009;27(4):382-90.
Necitumumab (IMC-11F8), a fully human IgG1 mAb directed against epidermal growth factor receptor for the intravenous treatment of cancer Dienstmann R, Tabernero J. Curr Opin Investig Drugs 2010;11(12):1434-41.
Recent developments in anti-cancer Agents targeting PI3K, Akt and mTORC1/2 Dienstmann R, Rodon J, Tabernero J. Recent Pat Anticancer Drug Discov 2011;6(2):210-36.
Targeting the PI3K-Akt-mTOR pathway – beyond rapalogs Markman B, Dienstmann R, Tabernero J. Oncotarget 2010;1(7):530-43.
BRAF as a target for cancer therapy Dienstmann R, Tabernero J. Anticancer Agents Med Chem 2011;11(3):285-95.
Molecular predictors of response to chemotherapy in colorectal cancer Dienstmann R, Vilar E, Tabernero J. Cancer J 2011;17(2):114-26.
Personalizing therapy with targeted agents in non-small cell lung cancer Dienstmann R, Martinez P, Felip E. Oncotarget 2011;2(3):165-77.
Combined modality therapy of stage IIIC breast cancer Dienstmann R, Branco LG, Rezende LM, Freitas LC, Lima CF, Rodrigues GJ, Noronha Filho H, Sarmento RMB, Small I, Bines J. Breast J 2011;17(3):331-3.
Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development Dienstmann R, Felip E. Expert Opin Biol Ther 2011;11(9):1223-31.
The development of molecular biomarkers in the individualized treatment of colorectal cancer De Mattos-Arruda L, Dienstmann D, Tabernero J. Clin Colorectal Cancer 2011;10(4):279-89.
Risk-benefit assessment of bevacizumab in the treatment of breast cancer Dienstmann R, Ades F, Saini KS, Metzger-Filho O. Drug Saf 2012;35(1):15-25.
Toxicity as biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGFR inhibiting anticancer agents Dienstmann R, Braña I, Rodon J, Tabernero J. Oncologist 2011;16(12):1729-40.
Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer Dienstmann R, De Dosso S, Felip E, Tabernero J. Mol Oncol 2012;6(1):15-26.
Application of monoclonal antibodies as cancer therapy in solid tumors Dienstmann R, Markman B, Tabernero J. Curr Clin Pharmacol 2012;7(2):137-45.
Panitumumab: summary of clinical development in colorectal cancer and future directions Argiles G, Dienstmann R, Tabernero J. Future Oncol 2012;8(4):373-89.
Molecular prescreening to select patient population in early clinical trials Rodón J, Saura C, Dienstmann R, Vivancos A, Cajal SR, Baselga J, Tabernero J. Nat Rev Clin Oncol 2012;9(6):359-66
Molecular profiling of patients with colorectal cancer and matched targeted therapy in Phase 1 clinical trials Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez ME, Alsina M, Capdevila J, Perez-Garcia J, Sánchez-Ollé G, Aura C, Prudkin L, Landolfi S, Hernández-Losa J, Vivancos A, Tabernero J. Mol Cancer Ther 2012;11(9):2062-71.
Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategies Dienstmann R, Rodon J, Tabernero J. Am Soc Clin Oncol Educ Book 2012;32:168-72.
Development of PI3K inhibitors: lessons learned from early clinical trials. Rodon J, Dienstmann R, Serra V, Tabernero J. Nat Rev Clin Oncol 2013;10(3):143-53.
Biomarker-driven patient selection for early clinical trials Dienstmann R, Rodon J, Barretina J, Tabernero J. Curr Opin Oncol 2013;25(3):305-12.
The genomic medicine frontier in human solid tumors: prospects and challenges Dienstmann R, Rodon J, Barretina J, Tabernero J. J Clin Oncol 2013;31(15):1874-84.
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J Annals Oncol 2014;25(3):552-63.
Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial Bines J, Dienstmann R, Obadia RM, Branco LGB, Quintella DC, Castro TM, Camacho PG, Soares F, Costa MEF Annals Oncol 2014;25(4):831-6.
Tumor Growth Rate (TGR) analysis in Phase I clinical trials–Letter. Dienstmann R, Tabernero J Clin Cancer Res 2014;20(9):2495-6.
Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors Dienstmann R, Rodon J, Serra V, Tabernero J Mol Cancer Ther 2014;13(5):1021-31.
Standardized decision support in sequencing reports of somatic cancer variants Dienstmann R, Dong F, Borger D, Dias-Santagata D, Ellisen LW, Le LP, Iafrate AJ Mol Oncol 2014;8(5):859-873.
The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning DienstmannR, Salazar R, Tabernero J Am Soc Clin Oncol Educ Book 2014;34:91-9.
Optimal design of trials to demonstrate the utility of genomically-guided therapy: putting Precision Cancer Medicine to the test Dienstmann R, Rodon J, Tabernero J Mol Oncol 2014;S1574-7891(14)00150-1.
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors Soria JC, DeBraud F, Bahleda R, Adamo B, Andre F, Dienstmann R, Delmonte A, Cereda R, Isaacson J, Litten J, Allen A, Dubois F, Saba C, Robert R, D’Incalci M, Zucchetti M, Camboni MG, Tabernero Ann Oncol 2014;25(11):2244-51.
Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR. Gastroenterology 2015;148(1):88-99.
Social interactomes for enabling research communities Guinney J, Dienstmann R, Ferté C, Friend S, McCormick F Cancer Discov 2014;4(11):1265-8.
Stepwise group sparse regression (SGSR): gene-set-based pharmacogenomic predictive models with stepwise selection of functional priors. Jang IS, Dienstmann R, Margolin AA, Guinney J. Pac Symp Biocomput 2015;20:32-43.
Intrinsic cancer subtypes – next steps into personalized medicine. Santos C, Sanz-Pamplona R, Nadal E, Grasselli J, Pernas S, Dienstmann R, Moreno V, Tabernero J, Salazar R. Cell Oncol (Dordr) 2015;38(1):3-16.
Genomic testing in colorectal cancer: how much is enough? Dienstmann R, Salazar R, Tabernero J. Oncology (Williston Park) 2015;29(3):186-8.
A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. Mau-Sørensen M, Dittrich C, Dienstmann R, Lassen U, Büchler W, Martinius H, Tabernero J. Cancer Chemother Pharmacol 2015;75(5):1065-73.
Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors Dienstmann R, Jang IS, Bot B, Friend S, Guinney J Cancer Discovery 2015;5(2):118-23.
Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients DienstmannR, Salazar R, Tabernero J J Clin Oncol 2015; 33(16):1787-96.
Safety and pharmacokinetics/pharmacodynamics of the first-in-class dual action HER3/EGFR antibody MEHD7945A in patients with locally advanced or metastatic epithelial tumors Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein Jr. GR, Tabernero J, Roda D, Calles A, Jimeno A, Wang A, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J Clin Cancer Res 2015;21(11):2462-70.
Heterogeneity of driver genes and therapeutic implications in colorectal cancer Dienstmann R, Cervantes A Annals Oncol 2015;26(8):1523-5.
Overcoming Resistance to anti-EGFR Therapy in Colorectal Cancer Dienstmann R, Salazar R, Tabernero J Am Soc Clin Oncol Educ Book 2015;35:e149-56.
Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BB, van der Post RS, Argilés G, Skartved NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J. Cancer Discov 2015;5(6):598-609.
Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit H, Stuyckens K, Chatterjee-Kishore M, Rodon J, Peddareddigari V, Luo FR, Soria J-C J Clin Oncol 2015;33(30):3401-8.
The consensus molecular subtypes of colorectal cancer Guinney J,Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. Nat Med 2015;21(11):1350-6.
MEK plus PI3K/mTORC1/2 therapeutic efficacy is impacted by TP53 mutation in preclinical models of colorectal cancer García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G,Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. Clin Cancer Res 2015;21(24):5499-510.
Tankyrase inhibition blocks Wnt/β-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer. Arques O, Chicote I, Puig I, Tenbaum SP, Argiles G,Dienstmann R, Fernandez N, Caratu G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espin E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Clin Cancer Res 2016;22(3):644-56.
First-in-man dose-escalation study of the selective BRAF inhibitor RG7256 in patients with BRAF V600-mutated advanced solid tumors Dienstmann R, Lassen U, Cebon J, Desai J, Brown MP, Evers S, Su F, Zhang W, Doisserie F, Lestini B, Schostack K, Meresse V, Tabernero J Target Oncol 2016;11(2):149-56.
Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies. Azuara D, Santos C, Lopez-Doriga A, Grasselli J, Nadal M, Sanjuan X, Marin F, Vidal J, Montal R, Moreno V, Bellosillo B, Argiles G, Elez E, DienstmannR, Montagut C, Tabernero J, Capellá G, Salazar R. Mol Cancer Ther 2016;15(5):1106-12.
Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment. Dienstmann R, Tabernero J. Cancer J 2016;22(3):149-55.
CIViC: A knowledgebase for expert-crowdsourcing the clinical interpretation of variants in cancer Griffith M, Spies NC, Krysiak K, Coffman AC, McMichael JF, Ainscough BJ, Rieke DJ, Danos AM, Kujan L, Ramirez CA, Wagner AH, Skidmore ZL, Liu CJ, Jones M, Bilski RL, Lesurf R, Barnell EK, Shah NM, Bonakdar M, Trani L, Matlock M, Ramu A, Campbell KM, Spies GC, Graubert AP, Karthik G, Eldred JM, Larson DE, Walker JR, Chu S, Bryan JN, Good BN, Wu C, Su AI, Dienstmann R, Jones SJM, Bose R, Spencer DH, Wartman LD, Wilson RK, Mardis ER, Griffith OL. Nat Genetics 2017;49(2):170-174.
Consensus Molecular Subtyping and the Evolution of Precision Medicine in Colorectal Cancer Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Nat Rev Cancer 2017;7(2):79-92.
Prediction of overall survival in stage II and III colon cancer beyond the American Joint Commission on Cancer TNM system: a retrospective, pooled biomarker study Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J. Ann Oncol 2017;28(5):1023-1031.
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Grasselli J, Elez E, Caratù G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Viéitez JM, Paéz D, Falcó E, Lopez Lopez C, Aranda E, Jones F, Sikri V, Nuciforo P, Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A. Ann Oncol 2017 Jun 1;28(6):1294-1301.
Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology. Garralda E, Dienstmann R, Tabernero J. Am Soc Clin Oncol Educ Book 2017;37:210-215.
Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer. McCleary NJ, Benson AB 3rd, Dienstmann R. Am Soc Clin Oncol Educ Book 2017;37:232-245.
Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights. Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J. Mol Oncol 2017;11(9):1263-1272.
Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells. Roumeliotis TI, Williams SP, Gonçalves E, Alsinet C, Del Castillo Velasco-Herrera M, Aben N, Ghavidel FZ, Michaut M, Schubert M, Price S, Wright JC, Yu L, Yang M, Dienstmann R, Guinney J, Beltrao P, Brazma A, Pardo M, Stegle O, Adams DJ, Wessels L, Saez-Rodriguez J, McDermott U, Choudhary JS. Cell Rep 2017;20(9):2201-2214.
Cancer: A precision approach to tumour treatment. Dienstmann R, Tabernero J. Nature 2017;548(7665):40-41.
Reply to the letter to the editor ‘Including lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer’ by Sciallero et al. Dienstmann R, Guinney J. Annals Oncol 2017;28(11)2889-2890.
Tumor side as model of integrative molecular classification of colorectal cancer. Dienstmann Clin Cancer Res 2018;24(5):989-990.
Colorectal cancer Consensus Molecular Subtypes translated to preclinical models uncover potentially targetable cancer-cell dependencies. Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama MA, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O,Dienstmann R, Lothe RA. Clin Cancer Res 2018;24(4):794-806.
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. Montagut C, Argilés G, Ciardiello F, Poulsen TT, DienstmannR, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J. JAMA Oncol 2018:e175245.
CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Smeby J, Sveen A, Merok MA, Danielsen SA, Eilertsen IA, Guren MG, DienstmannR, Nesbakken A, Lothe RA. Ann Oncol 2018; 29(5):1227-1234
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, Tusquets I, Albanell J, Rodon J, Tabernero J, de Torres C, DienstmannR, Gonzalez-Perez A, Lopez-Bigas N. Genome Med 2018;10(1):25.
TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence Puig I, Tenbaum SP, Chicote I, Arqués O, Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratù G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo AG, Terracciano L, Nuciforo P, Seoane J, Recio JA, Vivancos A, Dienstmann R, Tabernero J, Palmer HG. J Clin Invest. 2018 Jun 26. pii: 96393.
A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations. Tamborero D, Rubio-Perez C, Muiños F, Sabarinathan R, Piulats JM, Muntasell A, Dienstmann R, Lopez-Bigas N, Gonzalez-Perez A. Clin Cancer Res 2018;24(15):3717-3728.
Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. Dienstmann R, Salazar R, Tabernero J. Am Soc Clin Oncol Educ Book 2018;(38):231-238.
Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy. Allen WL, Dunne PD, McDade S, Scanlon E, Loughrey M, Coleman H, McCann C, McLaughlin K, Nemeth Z, Syed N, Jithesh P, Arthur K, Wilson R, Coyle V, McArt D, Murray GI, Samuel L, Nuciforo P, Jimenez J, Argiles G, Dienstmann R, Tabernero J, Messerini L, Nobili S, Mini E, Sheahan K, Ryan E, Johnston PG, Van Schaeybroeck S, Lawler M, Longley DB. JCO Precis Oncol 2018; Jun 13
Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Chang K, Willis JA, Reumers J, Taggart MW, San Lucas FA, Thirumurthi S, Kanth P, Delker DA, Hagedorn CH, Lynch PM, Ellis LM, Hawk ET, Scheet PA, Kopetz S, Arts J, Guinney J, Dienstmann R, Vilar E. Ann Oncol 2018;29(10):2061-2067.
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L. Ann Oncol 2018; 29(9):1895-1902
Should next-generation sequencing testing be routinely used in metastatic colorectal cancer? Dienstmann R, Ciner A, Hochster HS. Lancet Oncol 2018;19(11):1434-1435
Precision oncology: separating the wheat from the chaff. Remon J, Dienstmann R. ESMO Open 2018;3(6):e000446.
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dienstmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O’Connor MJ, Díez O, Balmaña J, Serra V. EMBO Mol Med 2018;10(12).
New clinical trial designs in the era of precision medicine. Garralda E, Dienstmann R, Piris-Giménez A, Braña I, Rodon J, Tabernero J.Mol Oncol 2019;13(3):549-557.
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. ESMO Open 2019;4(2):e000444
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients. Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gómez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Román S, Ponce J, Meléndez C, Carballas E, Dienstmann R, Oaknin A. Gynecol Oncol 2019;152(2):270-277.
Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Serna G, Ruiz-Pace F, Cecchi F, Fasani R, Jimenez J, Thyparambil S, Landolfi S, Elez ME, Vivancos A, Hembrough T, Tabernero J, Dienstmann R, Nuciforo P. Sci Rep 2019;9(1):13568.
Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes. Sveen A, Cremolini C, Dienstmann R. Ann Oncol 2019;30(11):1682-1685.
Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.Dienstmann R, Villacampa G, Sveen A, Mason MJ, Niedzwiecki D, Nesbakken A, Moreno V, Warren RS, Lothe RA, Guinney J. Ann Oncol 2019;30(10):1622-1629.
Capturing Hyperprogressive disease with immune checkpoint inhibitors using RECIST 1.1 criteria. Matos I, Martin-Liberal J, Garcia-Ruiz A, Hierro C, Ochoa de Olza M, Viaplana C, Azaro A, Vieito M, Brana I, Mur G, Ros J, Mateos J, Villacampa G, Berché R, Oliveira M, Alsina M, Élez E, Oaknin A, Muñoz-Couselo E, Carles J, Felip E, Rodon J, Tabernero J, Dienstmann R, Perez-Lopez R, Garralda E. Clin Cancer Res 2020;26(8):1846-1855.
Precision Therapy in RAS Mutant Colorectal Cancer. Dienstmann R, Connor K, Byrne AT; COLOSSUS Consortium. Gastroenterology 2020;158(4):806-811.
A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Wagner AH, Walsh B, Mayfield G, Tamborero D, Sonkin D, Krysiak K, Deu-Pons J, Duren RP, Gao J, McMurry J, Patterson S, Del Vecchio Fitz C, Pitel BA, Sezerman OU, Ellrott K, Warner JL, Rieke DT, Aittokallio T, Cerami E, Ritter DI, Schriml LM, Freimuth RR, Haendel M, Raca G, Madhavan S, Baudis M, Beckmann JS, Dienstmann R, Chakravarty D, Li XS, Mockus S, Elemento O, Schultz N, Lopez-Bigas N, Lawler M, Goecks J, Griffith M, Griffith OL, Margolin AA; Variant Interpretation for Cancer Consortium. Nat Genet 2020;52(4):448-457.
Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. Dienstmann R, Garralda E, Aguilar S, Sala G, Viaplana C, Ruiz-Pace F, González-Zorelle J, Grazia LoGiacco D, Ogbah Z, Ramos Masdeu L, Mancuso F, Fasani R, Jimenez J, Martinez P, Oaknin A, Saura C, Oliveira M, Balmaña J, Carles J, Macarulla T, Elez E, Alsina M, Braña I, Felip E, Tabernero J, Rodon J, Nuciforo P, Vivancos A. JCO Precis Oncol 2020;4:PO.19.00398.
Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity. Bruun J, Kryeziu K, Eide PW, Moosavi SH, Eilertsen IA, Langerud J, Røsok BI, Totland MZ, Brunsell TH, Pellinen T, Saarela J, Bergsland CH, Palmer HG, Brudvik KW, Guren T, Dienstmann R, Guren MG, Nesbakken A, Bjørnbeth BA, Sveen A, Lothe RA. Clin Cancer Res 2020, 26(15):4107-4119.
Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. Cedrés S, Ponce-Aix S, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez- Marti A, Gómez-Abecia S, Zucchiatti AC, Sansano I, Enguita AB, Miquel JM, Viaplana C, Dienstmann R, Paz-Ares L, Felip E. Clin Transl Oncol 2020;22(8):1390-1398.
Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, De Petris L, Yachnin J, Massard C, Opdam FL, Schlenk R, Vernieri C, Garralda E, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium, Calvo F, Fröhling S, Eggermont A, Apolone G, Voest EE, Caldas C, Tabernero J, Ernberg I, Rodon J, Lehtiö J. Nat Med 2020;26(7):992-994.
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. Ann Oncol 2020;S0923-7534(20):39971-3.
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Gris-Oliver A, Palafox M, Monserrat L, Brasó-Maristany F, Òdena A, Sánchez-Guixé M, Ibrahim YH, Villacampa G, Grueso J, Parés M, Guzmán M, Rodríguez O, Bruna A, Hirst CS, Barnicle A, de Bruin EC, Reddy A, Schiavon G, Arribas J, Mills GB, Caldas C, Dienstmann R, Prat A, Nuciforo P, Razavi P, Scaltriti M, Turner NC, Saura C, Davies BR, Oliveira M, Serra V. Clin Cancer Res 2020 ;26(14):3720-3731.
Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. Stjepanovic N, Villacampa G, Nead KT, Torres-Esquius S, Melis GG, Nathanson KL, Teule A, Brunet J, Y Cajal TR, Llort G, Dienstmann R, Rue M, Domchek SM, Balmaña J. Eur J Cancer 2020;132:53-60.
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype. Lupo B, Sassi F, Pinnelli M, Galimi F, Zanella ER, Vurchio V, Migliardi G, Gagliardi PA, Puliafito A, Manganaro D, Luraghi P, Kragh M, Pedersen MW, Horak ID, Boccaccio C, Medico E, Primo L, Nichol D, Spiteri I, Heide T, Vatsiou A, Graham TA, Élez E, Argiles G, Nuciforo P, Sottoriva A, Dienstmann R, Pasini D, Grassi E, Isella C, Bertotti A, Trusolino L. Sci Transl Med 2020;12(555):eaax8313.
Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Serna G, Ruiz-Pace F, Hernando J, Alonso L, Fasani R, Landolfi S, Comas R, Jimenez J, Elez E, Bullman S, Tabernero J, Capdevila J, Dienstmann R, Nuciforo P. Ann Oncol 2020;31(10):1366-1375.
Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer. Zunder SM, Perez-Lopez R, de Kok BM, Raciti MV, van Pelt GW, Dienstmann R, Garcia-Ruiz A, Meijer CA, Gelderblom H, Tollenaar RA, Nuciforo P, Wasser MN, Mesker WE. Eur J Radiol 2020;133:109345.
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. Martini G, Dienstmann R, Ros J, Baraibar I, Cuadra-Urteaga JL, Salva F, Ciardiello D, Mulet N, Argiles G, Tabernero J, Elez E. Ther Adv Med Oncol 2020;12:1758835920936089.
RBMS1 Suppresses Colon Cancer Metastasis through Targeted Stabilization of Its mRNA Regulon. Yu J, Navickas A, Asgharian H, Culbertson B, Fish L, Garcia K, Olegario JP, Dermit M, Dodel M, Hänisch B, Luo Y, Weinberg EM, Dienstmann R, Warren RS, Mardakheh FK, Goodarzi H. Cancer Discov 2020;10(9):1410-1423.
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Ligero M, Garcia-Ruiz A, Viaplana C, Villacampa G, Raciti MV, Landa J, Matos I, Martin-Liberal J, Ochoa-de-Olza M, Hierro C, Mateo J, Gonzalez M, Morales-Barrera R, Suarez C, Rodon J, Elez E, Braña I, Muñoz-Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Perez C, Seoane J, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez-Lopez R. Radiology 2021:200928.
Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil. Ferrari BL, Ferreira CG, Menezes M, De Marchi P, Canedo J, Melo AC, Jácome AA, Reinert T, Paes RD, Sodré B, Barrios CH, Dienstmann R. JCO Glob Oncol 2021;7:46-55.
Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients. Hernando-Calvo A, García-Alvarez A, Villacampa G, Ortiz C, Bodet D, García-Patos V, Recio JA, Dienstmann R, Muñoz-Couselo E. Clin Transl Oncol 2021;23(2):311-317.
Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis. Ligero M, Jordi-Ollero O, Bernatowicz K, Garcia-Ruiz A, Delgado-Muñoz E, Leiva D, Mast R, Suarez C, Sala-Llonch R, Calvo N, Escobar M, Navarro-Martin A, Villacampa G, Dienstmann R, Perez-Lopez R. Eur Radiol 2021;31(3):1460-1470.
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. Gris-Oliver A, Ibrahim YH, Rivas MA, García-García C, Sánchez-Guixé M, Ruiz-Pace F, Viaplana C, Pérez-García JM, Llombart-Cussac A, Grueso J, Parés M, Guzmán M, Rodríguez O, Anton P, Cozar P, Calvo MT, Bruna A, Arribas J, Caldas C, Dienstmann R, Nuciforo P, Oliveira M, Cortés J, Serra V. Br J Cancer 2021 Mar 15.
Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy. Saura C, Sánchez O, Martínez S, Domínguez C, Dienstmann R, Ruíz-Pace F, Céspedes MC, Peñuelas Á, Cortés J, Llurba E, Córdoba O. Cancers (Basel) 2021;13(4):923.